Dilute now while knowing the price will be higher down the road makes no sense (unless you are a charity wanting to donate shares, which Raj is NOT).
One possible argument could have been that the timing of the dilution was pre-determined but they could have easily canceled them stating "unfavorable market conditions"..
Rolontis, like all biologics, is heavily depending on process expertise. Take a look at all the CRL's in this space. Who the heck do you think will drive process development for Rolontis at SPPI?
Their CMC team can hardly fill a vial without a 483. You think they can manage a biologic?